ICOS and gastrointestinal stromal tumor: Therefore, exploitation of anti-ICOS antagonists, currently under investigation in the clinics (MEDI-570; NCT025250791), could be a promising therapeutic strategy to inhibit Tregs expansion in GIST patients.